WALTHAM, Massachusetts, August 10, 2026, 12:00 EDT — Sionna Therapeutics (SION.O) fell 92% after its study missed its main goal, sending the stock below the company’s reported gross cash position.
- Sionna Therapeutics NASDAQ:SION dropped 92.1% as of 11:58 EDT following failure in a Phase 2a trial.
- SION-719 resulted in a placebo-adjusted sweat chloride change of -1.0 mmol/L, with a p-value of 0.7.
- The company will not move forward with SION-719 as an addition to standard treatment.
- Gross cash and securities total $268.3 million, surpassing the implied equity value of $182.9 million.
Sionna Therapeutics NASDAQ:SION shares fell 92.1% to $4.05 around midday Monday. The company’s SION-719 add-on therapy did not meet a Phase 2a activity endpoint, prompting management to discontinue development for that indication.
The slump wiped out about $2.12 billion in equity value in a single session. Sionna was also left with a market value lower than its last reported gross cash and securities.
Shares of Vertex Pharmaceuticals NASDAQ:VRTX gained 6.9% after a competitive risk faded. The State Street SPDR S&P Biotech ETF (NYSEARCA:XBI) was little changed. Prices reflect trading as of 11:58 EDT.
| Security | Price | Day move | Investor read-through |
|---|---|---|---|
| Sionna Therapeutics NASDAQ:SION | $4.05 | -92.1% | Major clinical and pipeline overhaul |
| Vertex Pharmaceuticals NASDAQ:VRTX | $530.34 | +6.9% | Reduced competitive risk |
| State Street SPDR S&P Biotech ETF (NYSEARCA:XBI) | $157.25 | -0.1% | Sionna’s move not reflected in sector trend |
SION-719 was administered alongside Trikafta in a group of 15 adults with cystic fibrosis. Each participant carried two copies of the F508del mutation and was already on stable standard therapy.
The study found an average placebo-adjusted sweat chloride change of -1.0 mmol/L. The p-value stood at 0.7, indicating a lack of statistical significance.
Sionna pointed to atypical variability in sweat-chloride and inconsistent Trikafta exposure across periods, noting these issues are still being analyzed. However, these factors do not alter the unsuccessful endpoint outcome.
| Program | Population | Verified result | Current status |
|---|---|---|---|
| SION-719 plus Trikafta | 15 adults with cystic fibrosis | -1.0 mmol/L placebo-adjusted sweat chloride; p=0.7 | Program discontinued as add-on |
| SION-451 plus SION-2222 | Healthy volunteers; included in a Phase 1 trial with 120 participants | Achieved safety, tolerability and pharmacokinetic goals | This dual combination is preferred; future steps being evaluated |
| SION-451 plus SION-109 | Healthy volunteers; part of the same Phase 1 trial | Achieved safety, tolerability and pharmacokinetic goals | Not chosen as preferred combination |
SION-719 was tolerated well over the 14-day period. The majority of adverse events were mild to moderate, and no serious adverse events were reported. No serious events were recorded in the Phase 1 combination study either. Three participants discontinued participation across selected SION-2222 dosing cohorts.
President and Chief Executive Officer Mike Cloonan stated, “We are disappointed in the unexpected results from the Phase 2a trial.” Sionna obtained the topline data on Friday and is currently assessing its options for SION-451. Sionna release
Sionna disclosed having $268.3 million in cash, equivalents and marketable securities as of June 30. The company reported 45,212,399 shares outstanding as of July 31 in its most recent filing.
| Valuation measure | Value | Method |
|---|---|---|
| Gross cash and securities | $268.3 million | Company balance as of June 30 |
| Shares outstanding | 45.21 million | Filing from July 31 |
| Gross cash per share | $5.93 | Gross cash divided by shares outstanding |
| Implied equity value | $182.9 million | Quote of $4.045 times outstanding shares |
| Gross cash above equity value | $85.4 million | Gross cash minus implied equity value |
| Discount to gross cash per share | 31.8% | Quote against $5.93 |
The discount is notable but does not take effect automatically. It reflects gross cash rather than liquidation value or net cash available to shareholders.
Research expenses totaled $21.9 million in the second quarter. General and administrative spending reached $10.6 million. The company’s leadership intends to conserve capital as it evaluates its pipeline.
The first analyst moves following the readout were swift. Stifel, Wedbush, RBC and Raymond James each revised their ratings on Monday.
| Firm and analyst | Rating action | Price target | Signal |
|---|---|---|---|
| Stifel — Paul Matteis | Buy lowered to Hold | $55 down to $7 | Program value significantly cut |
| Wedbush — Laura Chico | Outperform downgraded to Neutral | $53 reduced to $5 | Trial failure led to revised forecasts |
| RBC — Brian Abrahams | Underperform upgraded to Sector Perform | $23 dropped to $5 | Lower price dismissed previous bearish stance |
| Raymond James — Christopher Raymond | Strong Buy changed to Market Perform | Not disclosed | Confidence pulled back |
RBC’s upgrade did not signal a bullish reversal, and its target dropped by 78% to $5. Remaining published targets now align closely with Sionna’s $5.93 gross cash per share number.
For Vertex, the outcome was more straightforward. “As such, we see today’s data as a clearing event for VRTX,” Abrahams said. Investor’s Business Daily
Risks are still high. SION-451 has data only from healthy volunteers. Sionna’s NBD1 approach is questioned by the failed patient trial. Gross cash may decline due to trials, contracts, leases, restructuring, and other obligations.
The upcoming key catalyst for the stock will be management’s announcement on its capital plan and the fate of SION-451 alongside SION-2222. Unless both are clearly valued, the difference between gross cash and current value serves as a buffer rather than supporting an investment case.
Related articles: Biotechnology
